Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GILEAD SCIENCES, INC.

(GILD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Gilead Sciences : Four-Year Biktarvy Data Presented at IAS 2021 Demonstrate High Efficacy and Durable Viral Suppression in Treatment-Naive Adults

07/19/2021 | 08:12am EDT

FOSTER CITY, Calif. - Gilead Sciences, Inc. (Nasdaq: GILD) announced a pooled analysis of a 48-week open-label extension of two Phase 3 studies (Study 1489 and Study 1490) shows 99% of participants who initiated treatment with Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) maintained an undetectable viral load (HIV-1 RNA

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about GILEAD SCIENCES, INC.
09/17GILEAD SCIENCES : Trodelvy Significantly Improved Quality of Life Over Standard ..
AQ
09/17GILEAD SCIENCES : New Data Demonstrate Trodelvy Survival Benefit in Metastatic T..
AQ
09/16GRITSTONE BIO : Oncology Places 5 Million Shares for $55 Million -- Stock Down 5..
MT
09/16VC DAILY : Venture Capitalists Push Back Against Drug-Pricing Bill
DJ
09/16GILEAD SCIENCES' : Late-Stage Study Shows Breast Cancer Drug May Improve Overall..
MT
09/16GILEAD SCIENCES : Trodelvy® Significantly Improved Quality of Life Over Standard..
BU
09/16GILEAD SCIENCES : New Data Demonstrate Trodelvy® Survival Benefit in Metastatic ..
BU
09/16Gilead Sciences, Inc Announces New Data Demonstrate Trodelvy Survival Benefit..
CI
09/16Gilead Says Trodelvy Improved Quality of Life in Breast Cancer in Study
DJ
09/14GILEAD SCIENCES, INC. : Ex-dividend day for
FA
More news
Analyst Recommendations on GILEAD SCIENCES, INC.
More recommendations
Financials (USD)
Sales 2021 24 999 M - -
Net income 2021 6 525 M - -
Net Debt 2021 23 112 M - -
P/E ratio 2021 14,2x
Yield 2021 3,95%
Capitalization 89 785 M 89 785 M -
EV / Sales 2021 4,52x
EV / Sales 2022 4,45x
Nbr of Employees 13 600
Free-Float 99,9%
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | MarketScreener
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 71,61 $
Average target price 76,38 $
Spread / Average Target 6,66%
EPS Revisions
Managers and Directors
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
Flavius Martin Executive Vice President-Research
Brett A. Pletcher Secretary, Chief Compliance Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
GILEAD SCIENCES, INC.22.91%89 785
BIONTECH SE340.60%86 750
WUXI APPTEC CO., LTD.35.75%69 350
REGENERON PHARMACEUTICALS34.93%67 775
VERTEX PHARMACEUTICALS-20.33%48 850
BEIGENE, LTD.56.02%37 507